ELISIO™-H

K260533 · Nipro Medical Corporation · KDI · Mar 19, 2026 · Gastroenterology, Urology

Device Facts

• Record ID: K260533
• Device Name: ELISIO™-H
• Applicant: Nipro Medical Corporation
• Product Code: KDI · Gastroenterology, Urology
• Decision Date: Mar 19, 2026
• Decision: SESE
• Submission Type: Special
• Regulation: 21 CFR 876.5860
• Device Class: Class 2
• Attributes: Therapeutic

Intended Use

ELISIO™-H dialyzers are intended for hemodialysis, hemodiafiltration, hemofiltration, and isolated ultrafiltration in patients with acute kidney injury or chronic kidney disease when conservative therapy is judged to be inadequate.

Device Story

ELISIO™-H is a single-use, high-flux hemodialyzer for extracorporeal treatment of renal failure. Device consists of a cylindrical housing with two compartments (blood and dialysate) separated by a semi-permeable POLYNEPHRON™ (polyethersulfone) membrane. Blood circulates through the blood compartment while dialysate flows counter-currently; enables removal of uremic toxins, excess fluid, and electrolytes via diffusion and/or convection. Interfaces with patient via ISO 8637 compliant blood tubing; requires dialysis machine with ultrafiltration controller or fluid balancing system. Used in clinical settings by trained healthcare professionals. Output is purified blood returned to patient; affects clinical decision-making by providing renal replacement therapy. Benefits include effective solute clearance and fluid management for patients with kidney injury or disease.

Clinical Evidence

No clinical testing conducted. Bench testing performed per ISO 8637-1:2024 and FDA guidance. Evaluated mechanical integrity (pressure, connectors) and performance (solute clearance for urea, creatinine, phosphate, Vitamin B12; sieving coefficients for albumin, inulin, β2-microglobulin/myoglobin; ultrafiltration rate/coefficient; blood volume; pressure drop; endotoxin transfer). Results demonstrate performance comparable to predicate devices.

Technological Characteristics

High-flux hemodialyzer; Polyethersulfone (POLYNEPHRON™) membrane; Polypropylene housing (BPA/DEHP-free). Eight sizes (0.9–2.5 m² surface area). Sterile (gamma radiation). ISO 8637-1:2024 compliant. No integrated electronics or software.

Indications for Use

Indicated for patients with acute kidney injury or chronic kidney disease requiring hemodialysis, hemodiafiltration, hemofiltration, or isolated ultrafiltration when conservative therapy is inadequate.

Regulatory Classification

Identification

A high permeability hemodialysis system is a device intended for use as an artificial kidney system for the treatment of patients with renal failure, fluid overload, or toxemic conditions by performing such therapies as hemodialysis, hemofiltration, hemoconcentration, and hemodiafiltration. Using a hemodialyzer with a semipermeable membrane that is more permeable to water than the semipermeable membrane of the conventional hemodialysis system (§ 876.5820), the high permeability hemodialysis system removes toxins or excess fluid from the patient's blood using the principles of convection (via a high ultrafiltration rate) and/or diffusion (via a concentration gradient in dialysate). During treatment, blood is circulated from the patient through the hemodialyzer's blood compartment, while the dialysate solution flows countercurrent through the dialysate compartment. In this process, toxins and/or fluid are transferred across the membrane from the blood to the dialysate compartment. The hemodialysis delivery machine controls and monitors the parameters related to this processing, including the rate at which blood and dialysate are pumped through the system, and the rate at which fluid is removed from the patient. The high permeability hemodialysis system consists of the following devices:(1) The hemodialyzer consists of a semipermeable membrane with an in vitro ultrafiltration coefficient (K uf ) greater than 8 milliliters per hour per conventional millimeter of mercury, as measured with bovine or expired human blood, and is used with either an automated ultrafiltration controller or anther method of ultrafiltration control to prevent fluid imbalance.(2) The hemodialysis delivery machine is similar to the extracorporeal blood system and dialysate delivery system of the hemodialysis system and accessories (§ 876.5820), with the addition of an ultrafiltration controller and mechanisms that monitor and/or control such parameters as fluid balance, dialysate composition, and patient treatment parameters (e.g., blood pressure, hematocrit, urea, etc.). (3) The high permeability hemodialysis system accessories include, but are not limited to, tubing lines and various treatment related monitors (e.g., dialysate pH, blood pressure, hematocrit, and blood recirculation monitors).

Special Controls

*Classification.* Class II. The special controls for this device are FDA's:(1) “Use of International Standard ISO 10993 ‘Biological Evaluation of Medical Device—Part I: Evaluation and Testing,’ ” (2) “Guidance for the Content of 510(k)s for Conventional and High Permeability Hemodialyzers,” (3) “Guidance for Industry and CDRH Reviewers on the Content of Premarket Notifications for Hemodialysis Delivery Systems,” (4) “Guidance for the Content of Premarket Notifications for Water Purification Components and Systems for Hemodialysis,” and (5) “Guidance for Hemodialyzer Reuse Labeling.”

Predicate Devices

• ELISIO™-H (K131935)
• ELISIO™-H (K140191)
• Optiflux (K203062)

Submission Summary (Full Text)

{0}

FDA U.S. FOOD & DRUG ADMINISTRATION

March 19, 2026

Nipro Medical Corporation
Jessica Oswald-Mcleod
Director, Regulatory Affairs
3150 NW 107th Ave.
Miami, Florida 33172

Re: K260533
Trade/Device Name: Elisio™-h
Regulation Number: 21 CFR 876.5860
Regulation Name: High Permeability Hemodialysis System
Regulatory Class: Class II
Product Code: KDI
Dated: February 19, 2026
Received: February 19, 2026

Dear Jessica Oswald-Mcleod:

We have reviewed your section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (the Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database available at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Additional information about changes that may require a new premarket notification are provided in the FDA guidance documents entitled "Deciding When to Submit a 510(k) for a Change to an Existing Device"

U.S. Food & Drug Administration
10903 New Hampshire Avenue
Silver Spring, MD 20993
www.fda.gov

{1}

K260533 - Jessica Oswald-Mcleod
Page 2

(https://www.fda.gov/media/99812/download) and "Deciding When to Submit a 510(k) for a Software Change to an Existing Device" (https://www.fda.gov/media/99785/download).

Your device is also subject to, among other requirements, the Quality Management System Regulation (QMSR) (21 CFR Part 820), which includes, but is not limited to, ISO 13485 clause 7.3 (Design controls), ISO 13485 clause 8.3 (Nonconforming product), ISO 13485 clause 8.5.2 (Corrective action), and ISO 13485 clause 8.5.3 (Preventative action). Please note that regardless of whether a change requires premarket review, the QMSR requires device manufacturers to review and approve changes to device design and production (ISO 13485 clause 7.3 and ISO 13485 clause 7.5) and document changes and approvals in the Medical Device File (ISO 13485 clause 4.2.3).

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR Part 803) for devices or postmarketing safety reporting (21 CFR Part 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products); good manufacturing practice requirements as set forth in the Quality Management System Regulation (QMSR) (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR Part 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR Parts 1000-1050.

All medical devices, including Class I and unclassified devices and combination product device constituent parts are required to be in compliance with the final Unique Device Identification System rule ("UDI Rule"). The UDI Rule requires, among other things, that a device bear a unique device identifier (UDI) on its label and package (21 CFR 801.20(a)) unless an exception or alternative applies (21 CFR 801.20(b)) and that the dates on the device label be formatted in accordance with 21 CFR 801.18. The UDI Rule (21 CFR 830.300(a) and 830.320(b)) also requires that certain information be submitted to the Global Unique Device Identification Database (GUDID) (21 CFR Part 830 Subpart E). For additional information on these requirements, please see the UDI System webpage at https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/unique-device-identification-system-udi-system.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-devices/medical-device-safety/medical-device-reporting-mdr-how-report-medical-device-problems.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email ([e-mail]) or phone [phone] or 301-796-7100).

{2}

K260533 - Jessica Oswald-Mcleod
Page 3

Sincerely,

**MAURA ROONEY -S**

Maura Rooney
Assistant Director
DHT3A: Division of Renal, Gastrointestinal, Obesity, and Transplant Devices
OHT3: Office of Gastrorenal, ObGyn, General Hospital, and Urology Devices
Office of Product Evaluation and Quality
Center for Devices and Radiological Health

Enclosure

{3}

FORM FDA 3881 (8/23)
Page 1 of 1
PSC Publishing Services [phone]
EF

| DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Indications for Use | Form Approved: OMB No. 0910-0120 Expiration Date: 07/31/2026 See PRA Statement below. |
| --- | --- |
| 510(k) Number (if known) K260533 | |
| Device Name ELISIOTM-H | |
| Indications for Use (Describe) ELISIOTM-H dialyzers are intended for hemodialysis, hemodiafiltration, hemofiltration, and isolated ultrafiltration in patients with acute kidney injury or chronic kidney disease when conservative therapy is judged to be inadequate. | |
| Type of Use (Select one or both, as applicable) ☑ Prescription Use (Part 21 CFR 801 Subpart D) ☐ Over-The-Counter Use (21 CFR 801 Subpart C) | |
| CONTINUE ON A SEPARATE PAGE IF NEEDED. | |
| This section applies only to requirements of the Paperwork Reduction Act of 1995. *DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.* | |
| The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to: Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff [e-mail] | |
| "An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number." | |

{4}

NIPRO

K260533 | 510(k) Summary: ELISIO™-H | Page 1

# 510(k) Summary - ELISIO™-H

## Contact Details (21 CFR 807.92(a)(1))

Applicant Name: Nipro Medical Corporation
Applicant Address: 3150 NW 107th Ave. Miami FL 33172 United States
Applicant Contact Telephone: [phone]
Applicant Contact: Mrs. Jessica Oswald-McLeod
Applicant Contact Email: [e-mail]
Preparation Date: March 13, 2026

## Device Name (21 CFR 807.92(a)(2))

Device Trade Name: ELISIO™-H
Common Name: High permeability hemodialysis system
Classification Name: Dialyzer, High Permeability With Or Without Sealed Dialysate System
Regulation Number: 876.5860

## Legally marketed predicate device (21 CFR 807.92(a)(3))

K131935, ELISIO™-H, Product Code KDI
K140191, ELISIO™-H, Product Code KDI
K203062, Optiflux, Product Code KDI

## Device Description Summary (21 CFR 807.92(a)(4))

The ELISIO™-H is a single-use, high-flux hemodialyzer intended for the extracorporeal treatment of patients with renal failure. The device is constructed of a plastic cylindrical housing comprised of two compartments, one for blood and one for dialysate, separated by a semi-permeable membrane. Blood is circulated through the blood compartment, while dialysate flows counter currently through the dialysate compartment. This flow pattern enables the removal of uremic toxins, excess fluid, and electrolytes via diffusion and/or convection, depending on the selected treatment modality.

The dialyzer interfaces with the patient via an ISO 8637 compliant blood tubing set and must be used with dialysis machines equipped with an ultrafiltration controller or accurate fluid balancing system. The ELISIO™-H features the POLYNEPHRON™ membrane (Polyethersulfone), for high clearance efficiency and a polypropylene housing not made with BPA or DEHP.

The device is available in eight sizes (surface area): 0.9, 1.1, 1.3, 1.5, 1.7, 1.9, 2.1, and 2.5 m². It is sterile (gamma radiation) and non-pyrogenic with a three-year shelf life. No integrated components or accessories are included.

NIPRO MEDICAL CORPORATION
3150 NW 107th Ave. | Miami, FL | 33172 USA
T: +1 305.599.7174
[e-mail] | www.nipro.com

{5}

NIPRO
K260533 | 510(k) Summary: ELISIO™-H | Page 2

# Intended Use/Indications for Use (21 CFR 807.92(a)(5))

ELISIO™-H dialyzers are intended for hemodialysis, hemodiafiltration, hemofiltration, and isolated ultrafiltration in patients with acute kidney injury or chronic kidney disease when conservative therapy is judged to be inadequate.

# Indications for Use Comparison (21 CFR 807.92(a)(5))

The subject device Indications for Use are expanded to include HDF, HF and ISO-UF from the currently cleared ELISIO™-H (K131935 and K140191) and identical to the secondary predicate, Optiflux (K203062).

# Technological Comparison (21 CFR 807.92(a)(6))

The subject device is identical in design, materials, manufacturing processes, sterilization method, shelf life, packaging and performance specifications to the currently cleared ELISIO™-H (K131935 and K140191).

Compared to the secondary predicate, Optiflux, the ELISIO™ H demonstrates equivalent high flux membrane performance and comparable solute transport, permeability, and operating characteristics in HDF modality, confirming that both devices share the same fundamental technological characteristics.

# Non-Clinical and/or Clinical Tests Summary & Conclusions (21 CFR 807.92(b))

Performance testing was conducted according to ISO 8637-1: 2024 - Extracorporeal systems for blood purification - Part 1: Haemodialysers, haemodiafilters, haemofilters and haemoconcentrators and the FDA Guidance for the Content of Premarket Notifications for Conventional and High Permeability Hemodialyzers. Testing included Mechanical Characteristics (Structural integrity: positive and negative pressure, Blood compartment integrity, Connectors verification) and Performance Characteristics (Solute clearance: Urea, Creatinine, Phosphate Vitamin B12; Sieving coefficients: albumin, inulin, and $\beta 2$-microglobulin or myoglobin; Ultrafiltration rate; Ultrafiltration coefficient; Blood compartment volume; Pressure drop; Endotoxin transfer (ANSI/AAMI ST72) and expiration date (ASTM F1980)).

No clinical testing was conducted for this submission.

Performance testing demonstrated that the ELISIO™-H hemodialyzer performs comparably to the predicate device with respect to solute clearance, membrane selectivity, and overall permeability. Hydraulic evaluations confirmed consistent high-flux performance and appropriate pressure characteristics, with no evidence of excessive permeability or protein loss. Materials are identical to those previously reviewed, and therefore no new materials-related risks were introduced. Collectively, the performance data demonstrate that the ELISIO™-H maintains the same intended use and fundamental technological characteristics as the predicate and supports a determination of substantial equivalence.

NIPRO MEDICAL CORPORATION
3150 NW 107th Ave. | Miami, FL | 33172 USA
T: +1 305.599.7174
[e-mail] | www.nipro.com